Search Results - "van Nunen, A. B."

  • Showing 1 - 16 results of 16
Refine Results
  1. 1

    Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase by van Nunen, A B, Hansen, B E, Suh, D J, Löhr, H F, Chemello, L, Fontaine, H, Heathcote, J, Song, B C, Janssen, H L A, de Man, R A, Schalm, S W

    Published in Gut (01-03-2003)
    “…Background and aims: Interferon (IFN) induced hepatitis B e antigen (HBeAg) seroconversion is durable in 80–90% of chronic hepatitis B patients. Preliminary…”
    Get full text
    Journal Article
  2. 2

    Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection by van Zonneveld, M., van Nunen, A. B., Niesters, H. G. M., de Man, R. A., Schalm, S. W., Janssen, H. L. A.

    Published in Journal of viral hepatitis (01-07-2003)
    “…Vertical transmission of hepatitis B virus (HBV) can occur occasionally despite vaccination of the child. This vaccination breakthrough has been associated…”
    Get full text
    Journal Article
  3. 3

    Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus by Wolters, L. M. M., Van Nunen, A. B., Honkoop, P., Vossen, A. C. T. M., Niesters, H. G. M., Zondervan, P. E., De Man, R. A.

    Published in Journal of viral hepatitis (01-11-2000)
    “…Currently, the best option for patients with hepatitis delta is interferon alpha therapy for at least one year. To evaluate the effect of the combination…”
    Get full text
    Journal Article
  4. 4

    Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue? by Van Nunen, A. B., De Man, R. A., Heijtink, R. A., Vossen, A. C. T. M., Schalm, S. W.

    Published in Journal of viral hepatitis (01-05-2002)
    “…In view of the limited efficacy of lamivudine monotherapy for chronic hepatitis B (HBV) infection, combination with other drugs seems logical. Intravenous…”
    Get full text
    Journal Article
  5. 5

    Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug? by van Nunen, A.B, Janssen, H.L.A, Wolters, L.M.M, Niesters, H.G.M, de Man, R.A, Schalm, S.W

    Published in Antiviral research (01-11-2001)
    “…For the treatment of chronic hepatitis B (CHB) two drugs have been licensed world-wide: interferon-alpha (IFN) and lamivudine. Both drugs significantly…”
    Get full text
    Journal Article Conference Proceeding
  6. 6

    Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes by Heijtink, R.A., van Nunen, A.B., van Bergen, P., Östberg, L., Osterhaus, A.D.M.E., de Man, R.A.

    Published in Journal of medical virology (01-08-2001)
    “…A human monoclonal anti‐hepatitis B antibody preparation (TUVIRUMAB) was administered 6 times over a 2‐week period in a dose‐escalating scheme to chronic…”
    Get full text
    Journal Article
  7. 7

    Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort by Schoon, E J, van Nunen, A B, Wouters, R S, Stockbrügger, R W, Russel, M G

    “…Reduced bone mineral density (BMD) has been reported in 3-77% of patients with inflammatory bowel disease (IBD). The majority of these studies are…”
    Get more information
    Journal Article
  8. 8
  9. 9

    Contrasting patterns of response to lamivudine monotherapy in chronic hepatitis B patients by Wolters, L M, van Nunen, A B, Niesters, H G, de Man, R A

    “…In this paper we describe a cohort of patients treated with lamivudine, a reverse transcriptase inhibitor with a strong virus-suppressive effect on the…”
    Get more information
    Journal Article
  10. 10
  11. 11

    Suppression of hepatitis B virus replication mediated by hepatitis A-induced cytokine production by Van Nunen, Andeltje B., Pontesilli, Oscar, Uytdehaag, Fons, Osterhaus, Albert D. M. E., De Man, Robert A.

    Published in Liver (Copenhagen) (01-02-2001)
    “…: Background: Acute hepatitis A virus (HAV) infection can cause severe hepatitis especially in patients with underlying chronic liver disease. In patients with…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients by Van Nunen, Andeltje B., Baumann, Matthias, Manns, Michael P., Reichen, J., Spengler, U., Marschner, Jens-Peter, De Man, Robert A.

    Published in Liver (Copenhagen) (01-06-2001)
    “…: Background/Aims: In this study the safety and efficacy of a monoclonal anti‐HBs, Tuvirumab (Mab), were investigated. Tuvirumab is a human monoclonal antibody…”
    Get full text
    Journal Article
  14. 14

    Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome by Janssen, Harry LA, van Zonneveld, Monika, van Nunen, Andeltje B, Niesters, Hubert GM, Schalm, Solko W, de Man, Robert A

    “…Polyarteritis nodosa (PAN) is a systemic inflammatory disease causing vasculitis of medium sized and small arteries. Circulating immune complexes containing…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Hepatitis B virus-specific T cell response in chronic hepatitis B patients treated with lamivudine and interferon-α by Pontesilli, Oscar, Van Nunen, Andeltje B., Van Riel, Debby, Carotenuto, Patrizia, Niesters, Hubert G., Uytdehaag, Fons G., De Man, Robert A., Osterhaus, Albert D.

    Published in Liver international (01-08-2004)
    “…: Aims: The goal of the present study was to assess the impact combination antiviral therapy has on immune responses in chronic hepatitis B. Materials and…”
    Get full text
    Journal Article